Diabetes mellitus (DM) is accompanied by several cardiovascular complications such as coronary artery disease, atherosclerosis, hypertension, cerebral and myocardial infarction, etc. DM induces the alteration of platelet functions including activation, hyperaggregation, adhesiveness, and formation of thrombi. Release of AA from phospholipids of the PM, synthesis of TxA 2 ,PGE 2 , activity of PLA 2 , and PLC are increased in the platelets of the DM patients. Stimulation of PLA 2 activity and accumulation of bioactive metabolites such as AA, its oxygenated derivatives, prostaglandins and PAF can evoke glucose production, also. In this study we explored the effect of the 1,4-dihydropyridine compound cerebrocrast at a low concentration (10 À 6 ±10 À 8 m) on the level of intracellular calcium in unstimulated human platelets and those stimulated with thrombin as well as release of [ 3 H] AA from phospholipids of platelet PM. Cerebrocrast at a concentration of 10 À 6 m decreased the basal level of intracellular calcium concentration (platelets were loaded with Fura-2) in unstimulated as well as in thrombin stimulated platelets. Cerebrocrast at concentrations of 10 À 6 , 10 À 7 , 10 À 8 m inhibited release of [ 3 H] AA from phospholipids of platelet PM. We conclude that blockade of human platelet activation with cerebrocrast can prevent aggregation, adhesion and formation of thrombi. The inhibition of [ 3 H] AA release from phospholipids of platelet PM can prevent formation of eicosanoids such as TxA 2 , PGG 2 , and PGH 2 plus AA oxygenated derivatives. These effects of cerebrocrast are very signi®cant in the treatment of DM-evoked cardiovascular complications.